Michael K. Badman

6.1k total citations · 3 hit papers
30 papers, 4.8k citations indexed

About

Michael K. Badman is a scholar working on Molecular Biology, Surgery and Physiology. According to data from OpenAlex, Michael K. Badman has authored 30 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 11 papers in Surgery and 8 papers in Physiology. Recurrent topics in Michael K. Badman's work include Fibroblast Growth Factor Research (7 papers), Epigenetics and DNA Methylation (5 papers) and Pediatric Hepatobiliary Diseases and Treatments (5 papers). Michael K. Badman is often cited by papers focused on Fibroblast Growth Factor Research (7 papers), Epigenetics and DNA Methylation (5 papers) and Pediatric Hepatobiliary Diseases and Treatments (5 papers). Michael K. Badman collaborates with scholars based in United States, United Kingdom and Japan. Michael K. Badman's co-authors include Jeffrey S. Flier, Eleftheria Maratos–Flier, Pavlos Pissios, Adam R. Kennedy, Γεώργιος Κούκος, Ffolliott M. Fisher, Alexei Kharitonenkov, Anja Köester, Gosala Gopalakrishnan and Patricia C. Chui and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Michael K. Badman

30 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hepatic Fibroblast Growth Factor 21 Is Regulated by PPARα and Is a Key Mediator of Hepatic Lipid Metabolism in Ketotic States

2007 1.3k citations Michael K. Badman, Pavlos Pissios et al. Cell Metabolism profile →
Kisspeptin-54 Stimulates the Hypothalamic-Pituitary Gonadal Axis in Human Males

2005 523 citations Waljit S. Dhillo, Owais B. Chaudhri et al. The Journal of Clinical Endocrinology & Metabolism profile →
Serum Bile Acids Are Higher in Humans With Prior Gastric Bypass: Potential Contribution to Improved Glucose and Lipid Metabolism

2009 455 citations Mary‐Elizabeth Patti, Sander M. Houten et al. Obesity profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael K. Badman United States	22	2.6k	1.3k	1000	949	772	30	4.8k
Yasuhiko Okimura Japan	35	997 0.4×	1.0k 0.8×	410 0.4×	863 0.9×	1.7k 2.2×	117	3.8k
Koshi Hashimoto Japan	35	1.1k 0.4×	630 0.5×	897 0.9×	519 0.5×	1.7k 2.2×	142	3.6k
Lisa Hahner United States	21	1.1k 0.4×	648 0.5×	579 0.6×	441 0.5×	641 0.8×	24	3.0k
Blerina Kola United Kingdom	31	1.1k 0.4×	1.6k 1.2×	1.2k 1.2×	749 0.8×	2.1k 2.7×	57	5.5k
Tetsuya Tagami Japan	30	987 0.4×	1.1k 0.8×	712 0.7×	495 0.5×	1.8k 2.3×	118	4.5k
Ingrid Wernstedt Asterholm Sweden	30	1.1k 0.4×	2.1k 1.6×	438 0.4×	2.0k 2.1×	394 0.5×	64	4.2k
Mariana P. Monteiro Portugal	31	577 0.2×	985 0.7×	900 0.9×	267 0.3×	853 1.1×	157	3.1k
O. Schmitz Denmark	34	1.7k 0.7×	1.5k 1.1×	1.3k 1.3×	328 0.3×	2.8k 3.7×	113	4.9k
WuQiang Fan United States	17	1.2k 0.5×	980 0.7×	507 0.5×	645 0.7×	535 0.7×	28	3.1k
Sarah L. Gray Canada	22	1.3k 0.5×	929 0.7×	363 0.4×	546 0.6×	301 0.4×	42	2.7k

Countries citing papers authored by Michael K. Badman

Since Specialization

Citations

This map shows the geographic impact of Michael K. Badman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael K. Badman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael K. Badman more than expected).

Fields of papers citing papers by Michael K. Badman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael K. Badman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael K. Badman. The network helps show where Michael K. Badman may publish in the future.

Co-authorship network of co-authors of Michael K. Badman

This figure shows the co-authorship network connecting the top 25 collaborators of Michael K. Badman. A scholar is included among the top collaborators of Michael K. Badman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael K. Badman. Michael K. Badman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Frías, Juan P., Robert Schmouder, Eric Lawitz, et al.. (2025). Clinical trial: A Phase 2 Randomised Platform Study to Assess Monotherapy and Combination Treatment Regimens in Metabolic Dysfunction–Associated Steatohepatitis. Alimentary Pharmacology & Therapeutics. 63(5). 637–647. 1 indexed citations

Schramm, Christoph, Heiner Wedemeyer, Andrew L. Mason, et al.. (2022). Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis. JHEP Reports. 4(11). 100544–100544. 37 indexed citations

Badman, Michael K., Sachin N. Desai, Soniya Vaidya, et al.. (2019). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non–Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers. Clinical Pharmacology in Drug Development. 9(3). 395–410. 59 indexed citations

Camilleri, Michael, Sara Linker Nord, Duane Burton, et al.. (2019). 976 – A Double-Blind, Randomized, Placebo-Controlled, Crossover, Multiple-Dose Study of Tropifexor, a Non Bile Acid Fxr Agonist, in Patients with Primary Bile Acid Diarrhea. Gastroenterology. 156(6). S–204. 5 indexed citations

Laffitte, Bryan, Paul V. Rucker, D. CHIANELLI, et al.. (2018). LJN452 (tropifexor) attenuates steatohepatitis, inflammation, and fibrosis in dietary mouse models of nonalcoholic steatohepatitis. Journal of Hepatology. 68. S341–S342. 2 indexed citations

Schramm, Christoph, Gideon M. Hirschfield, Andrew L. Mason, et al.. (2018). Early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis: An interim analysis of an ongoing phase 2 study. Journal of Hepatology. 68. S103–S103. 25 indexed citations

Huttner, Kenneth, Marc F. DeCristofaro, Bryan Laffitte, et al.. (2017). First-in-Human study of LMB763, a novel, orally-available farnesoid X receptor agonist that demonstrates modulation of the pharmacodynamic markers FGF19 and C4 in healthy subjects. Journal of Hepatology. 66(1). S425–S425. 2 indexed citations

Dushay, Jody, Patricia C. Chui, Gosala Gopalakrishnan, et al.. (2010). Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease. Gastroenterology. 139(2). 456–463. 499 indexed citations

Adams, Andrew C., Inna Astapova, Ffolliott M. Fisher, et al.. (2010). Thyroid Hormone Regulates Hepatic Expression of Fibroblast Growth Factor 21 in a PPARα-dependent Manner. Journal of Biological Chemistry. 285(19). 14078–14082. 116 indexed citations

10.

Patti, Mary‐Elizabeth, Sander M. Houten, Antônio C. Bianco, et al.. (2009). Serum Bile Acids Are Higher in Humans With Prior Gastric Bypass: Potential Contribution to Improved Glucose and Lipid Metabolism. Obesity. 17(9). 1671–1677. 455 indexed citations breakdown →

11.

Badman, Michael K. & Jeffrey S. Flier. (2007). The Adipocyte as an Active Participant in Energy Balance and Metabolism. Gastroenterology. 132(6). 2103–2115. 206 indexed citations

12.

Badman, Michael K., Pavlos Pissios, Adam R. Kennedy, et al.. (2007). Hepatic Fibroblast Growth Factor 21 Is Regulated by PPARα and Is a Key Mediator of Hepatic Lipid Metabolism in Ketotic States. Cell Metabolism. 5(6). 426–437. 1263 indexed citations breakdown →

13.

Kievit, Paul, Jane K. Howard, Michael K. Badman, et al.. (2006). Enhanced leptin sensitivity and improved glucose homeostasis in mice lacking suppressor of cytokine signaling-3 in POMC-expressing cells. Cell Metabolism. 4(2). 123–132. 187 indexed citations

14.

Dhillo, Waljit S., Owais B. Chaudhri, Michael Patterson, et al.. (2005). Kisspeptin-54 Stimulates the Hypothalamic-Pituitary Gonadal Axis in Human Males. The Journal of Clinical Endocrinology & Metabolism. 90(12). 6609–6615. 523 indexed citations breakdown →

15.

Pearson, Ewan R., Michael K. Badman, P M Clark, et al.. (2004). Contrasting Diabetes Phenotypes Associated With Hepatocyte Nuclear Factor-1α and -1β Mutations. Diabetes Care. 27(5). 1102–1107. 102 indexed citations

16.

Bingham, Coralie, Sian Ellard, William G. van’t Hoff, et al.. (2003). Atypical familial juvenile hyperuricemic nephropathy associated with a hepatocyte nuclear factor-1β gene mutation. Kidney International. 63(5). 1645–1651. 110 indexed citations

17.

Badman, Michael K. & T A Chowdhury. (2002). Should thyroid function tests be done annually in all patients with diabetes?. Diabetic Medicine. 19(s3). 7–9. 11 indexed citations

18.

Badman, Michael K., Rhys Pryce, Sophie Chargé, John F. Morris, & Anne Clark. (1998). Fibrillar islet amyloid polypeptide (amylin) is internalised by macrophages but resists proteolytic degradation. Cell and Tissue Research. 291(2). 285–294. 34 indexed citations

19.

Badman, Michael K., et al.. (1996). Processing of pro‐islet amyloid polypeptide (proIAPP) by the prohormone convertase PC2. FEBS Letters. 378(3). 227–231. 49 indexed citations

20.

Clark, Anne, Sophie Chargé, Michael K. Badman, & Eelco J.P. de Koning. (1996). Islet amyloid in type 2 (non-insulin-dependent) diabetes. Apmis. 104(1-6). 12–18. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact